DNA vs. ACAD, CRNX, ZLAB, MTSR, DNLI, XENE, MOR, TWST, VCEL, and CPRX
Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include ACADIA Pharmaceuticals (ACAD), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Metsera (MTSR), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Twist Bioscience (TWST), Vericel (VCEL), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.
Ginkgo Bioworks vs.
Ginkgo Bioworks (NYSE:DNA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
Ginkgo Bioworks has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the S&P 500.
ACADIA Pharmaceuticals has higher revenue and earnings than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Ginkgo Bioworks had 6 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 12 mentions for Ginkgo Bioworks and 6 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 0.74 beat Ginkgo Bioworks' score of 0.36 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.
Ginkgo Bioworks currently has a consensus target price of $4.58, suggesting a potential downside of 57.85%. ACADIA Pharmaceuticals has a consensus target price of $24.00, suggesting a potential upside of 20.30%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Ginkgo Bioworks.
ACADIA Pharmaceuticals has a net margin of 13.83% compared to Ginkgo Bioworks' net margin of -298.78%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Ginkgo Bioworks' return on equity.
ACADIA Pharmaceuticals received 869 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 73.08% of users gave ACADIA Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote.
Summary
ACADIA Pharmaceuticals beats Ginkgo Bioworks on 16 of the 18 factors compared between the two stocks.
Get Ginkgo Bioworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ginkgo Bioworks Competitors List
Related Companies and Tools
This page (NYSE:DNA) was last updated on 2/22/2025 by MarketBeat.com Staff
